A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjogren's syndrome

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjogren's syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs CFZ 533 (Primary) ; CFZ 533 (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 Feb 2017 Planned End Date changed from 1 Feb 2017 to 29 May 2018.
    • 20 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 29 May 2018.
    • 18 Mar 2016 Protocol amended as treatment arms changed from 2 to 4 and drug will be given intravenously also as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top